Roundhill Innov-100 0DTE Covered Call Strat ETF vs Revvity Inc — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.6, while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc pays a 0.25% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Revvity Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| QDTE | RVTY | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $36.60 | $117.75 |
52-Week Low | $26.85 | $82.26 |
Market Cap | — | $12.33B |
Enterprise Value | — | $14.82B |
Dividend Yield | — | 0.25% |
Signals from Pluang's Aura AI — not financial advice
QDTE trades at $29.22, up 0.31% on the day, with technical indicators signaling a bearish trend. The ETF employs a weekly covered call strategy on the Innovation-100 index, generating high distribution yields. Recent news highlights scrutiny over its fee structure and yield sustainability amid declining volatility. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook is cautious due to bearish technicals and yield compression risks. Opportunities exist for income-focused investors seeking weekly distributions, but risks include fee drag and volatility dependence. Investor sentiment is mixed, with media questioning yield math while acknowledging competitive returns in certain periods.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Trailing returns across standard periods
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →